Abstract

Research aimed at enhancing the efficacy of organometallic complexes against cancer, has shown that attaching bio‐active molecules to (metallo)drugs often enhances their biological properties. New salicylaldimine and 2‐pyridylimine ligands (L2 and L3), containing a bio‐active acridine scaffold, were synthesized and complexed to Rh(III), Ir(III), Ru(II) and Os(II) metal ion centers. The resulting acridine‐containing half‐sandwich complexes have been characterized fully by elemental analysis, FT‐IR and NMR spectroscopy, HR‐ESI mass spectrometry as well as single crystal X‐ray diffraction, for the Rh(III) N^N bidentate complex [RhCp*Cl(L3)][BPh4]. The antiproliferative activity of the ligands (L2 and L3) and complexes (C1 to C9) were evaluated in vitro against human promyelocytic leukemia cells (HL60) and normal skin fibroblast cells (FG0). The compounds exhibit good activities against HL60 cells and are consistently selective towards cancerous cells over non‐tumorous cells. This study demonstrates the potential of such hybrid compounds to target cancer cells specifically. The most active complex, [RhCp*Cl(L2)], exhibited binding to DNA model guanosine‐5’‐monophosphate (5’‐GMP) which suggests a mode of action involving interaction of the complex with 5’‐GMP found on DNA backbone.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.